Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Muni Hu, Xiaolin Lin, Tiantian Sun, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 23

Showing 23 citing articles:

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1440-1440
Open Access | Times Cited: 13
Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis
Xinpei Li, Shijie Shang, Meng Wu, et al.
Cancer Letters (2024) Vol. 598, pp. 217096-217096
Closed Access | Times Cited: 9
Gut microbiome and immune checkpoint inhibitor toxicity
Rik J. Verheijden, Mick J M van Eijs, Fernanda L. Paganelli, et al.
European Journal of Cancer (2025) Vol. 216, pp. 115221-115221
Closed Access | Times Cited: 1
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
Chengpei Zhu, Chenchen Zhang, Shanshan Wang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e008686-e008686
Open Access | Times Cited: 6
The Role of the Microbiome in Cancer Therapies
Julia Chalif, Naomi E. Goldstein, Yogita Mehra, et al.
Hematology/Oncology Clinics of North America (2025)
Closed Access
Immuno-oncology in the daily practice
Ariane Laparra
Current Opinion in Oncology (2025)
Closed Access
Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses
Xiaoqiang Zhu, Muni Hu, Xiaowen Huang, et al.
Cell Metabolism (2025)
Closed Access
Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
Cancers (2025) Vol. 17, Iss. 6, pp. 1001-1001
Open Access
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Gut microbiome and tumor immunotherapy
Mohini Vig, Shweta Dubey
International review of cell and molecular biology (2025)
Closed Access
Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
Qimei Fang, Qian Yan, Zhaolu Xie, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses
Jacopo Canzian, Fabio Conforti, Flavia Jacobs, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1054-1054
Open Access
The therapeutic promise of probiotic Bacteroides fragilis (BF839) in cancer immunotherapy
Kunwei Peng, Yuqing Li, Qijun Yang, et al.
Frontiers in Microbiology (2025) Vol. 16
Open Access
Dermatologic toxicities related to cancer immunotherapy
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, et al.
Toxicology Reports (2025), pp. 102021-102021
Open Access
Precision Immunomodulation: Understanding and Harnessing Cytokine Pathways to Treat and Prevent Immune-Related Adverse Events (irAEs)
Matthew J. Hadfield, Ross D. Merkin, Sherin J. Rouhani, et al.
Best Practice & Research Clinical Haematology (2025), pp. 101625-101625
Closed Access
Metagenomic approaches and opportunities in arid soil research
Muhammad Ejaz, Kareem Rady Badr, Zahoor Ul Hassan, et al.
The Science of The Total Environment (2024) Vol. 953, pp. 176173-176173
Closed Access | Times Cited: 2
Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center
Severin Rodler, Can Aydogdu, Isabel Brinkmann, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2246-2246
Open Access | Times Cited: 1
Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management
Sandra Gofinet Pasoto, André Silva Franco, Clóvis A. Silva, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 10, pp. 1149-1167
Closed Access | Times Cited: 1
Decoding the microbiota metabolome in hepatobiliary and pancreatic cancers: Pathways to precision diagnostics and targeted therapeutics
Yuemiao Xu, Jiahan Le, Jiang‐Jiang Qin, et al.
Pharmacological Research (2024) Vol. 208, pp. 107364-107364
Open Access | Times Cited: 1
From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy
David Dora, Emőke Szőcs, Ádám Soós, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
Evangelos Triantafyllou, Cathrin Gudd, Lucia Possamai
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
A two-stage ensemble learning based prediction and grading model for PD-1/PD-L1 inhibitor-related cardiac adverse events: a multicenter retrospective study
Xitong Cheng, Zhaochun Wu, Jierong Lin, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 255, pp. 108360-108360
Closed Access
Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database
Huaju Yang, Rendong Huang, Ping Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Causal relationship between gut microbiota and lung squamous cell carcinoma: a bidirectional two-sample Mendelian randomization study
Weijian Song, Jianwei Shi, Minjun Du, et al.
Postgraduate Medical Journal (2024)
Closed Access
Page 1

Scroll to top